1. Indications:

Deucrava (Deucravacitinib) 6 mg is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

2. Pharmacology:

Deucrava (Deucravacitinib) 6 mg exerts its pharmacological effects by selectively inhibiting Janus kinases (JAKs), particularly JAK1, JAK2, and Tyrosine kinase 2 (TYK2). By blocking these enzymes, Deucrava interferes with the signaling pathways involved in the immune response, thereby reducing inflammation and slowing down the abnormal cell growth associated with psoriasis.

3. Dosage and Administration:

The recommended dosage of Deucrava (Deucravacitinib) 6 mg is one tablet taken orally once daily, with or without food. Treatment should be continued as long as the patient experiences clinical benefit and tolerates the medication well. Dose adjustments or discontinuation may be necessary based on individual patient response and tolerability.

4. Interaction:

Deucrava (Deucravacitinib) 6 mg may interact with other medications, including:

• Strong CYP3A4 inhibitors or inducers: Co-administration with drugs that affect CYP3A4 metabolism may alter the plasma concentration of Deucrava.
• Live vaccines: Concomitant use of live vaccines with Deucrava may result in reduced vaccine efficacy.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Deucrava (Deucravacitinib) 6 mg may include:

• Upper respiratory tract infections
• Headache
• Diarrhea
• Nausea
• Elevated liver enzymes
• Fatigue

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Deucrava (Deucravacitinib) 6 mg, patients should be aware of the following precautions:

• Deucrava may increase the risk of serious infections, including tuberculosis and opportunistic infections. Patients should be monitored for signs of infection during treatment.
• Patients with a history of liver disease or elevated liver enzymes may be at increased risk of hepatotoxicity with Deucrava. Liver function tests should be performed before starting treatment and periodically thereafter.
• Deucrava may increase the risk of malignancies, including lymphoma and skin cancer. Patients should undergo regular skin examinations and be monitored for signs of malignancy during treatment.

7. Overdose Effects:

In case of overdose with Deucrava (Deucravacitinib) 6 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Deucrava overdose, and patients should seek immediate medical attention if overdose is suspected.